ReachRxResearch
Home
Research
Sign Up
Dietary Fat Intake and Mortality Among Patients With Nonmetastatic Prostate Cancer
Back to Research Hub
  1. Home
  2. Research Hub
  3. Dietary Fat Intake and Mortality Among P…

Dietary Fat Intake and Mortality Among Patients With Nonmetastatic Prostate Cancer

JAMA Network Open·September 2Open Access
Medicine, General & InternalPractice changingProstate CancerProspective Cohort StudyDietary Fat InterventionNutrition / DietOlder Adult

Summary

View source

What was studied

This prospective cohort study (nested in the Health Professionals Follow-Up Study) examined whether post-diagnosis dietary fat type was associated with long-term mortality in 4,884 men with nonmetastatic (T1–T3) prostate cancer, diagnosed 1986–2019 and followed through December 2022 (median 12.8 years).

Key findings

Higher saturated fat intake (Q5 vs. Q1) was linked to greater all-cause mortality (HR 1.24, 95% CI 1.05–1.47) and cardiovascular mortality (HR 1.42, 95% CI 1.02–1.98). Substituting 5% of calories from saturated fat with monounsaturated fat reduced all-cause mortality (HR 0.80, 95% CI 0.70–0.91); substituting 10% of animal fat calories with plant-based fat also reduced it (HR 0.84, 95% CI 0.76–0.93). No dietary fat type was associated with prostate cancer–specific mortality.

Study limitations

- Observational design; residual confounding from unmeasured dietary and lifestyle factors cannot be excluded. - Study population was predominantly White male health professionals, limiting generalizability. - Dietary fat was measured by self-reported food frequency questionnaire every 4 years, introducing measurement error.

Clinical implications

Counsel nonmetastatic prostate cancer survivors to shift away from saturated and animal fats toward plant-based and monounsaturated fat sources to lower cardiovascular and all-cause mortality risk. These changes will not affect prostate cancer–specific death but may meaningfully improve overall survival.

Caveats

  • Prostate cancer–specific mortality showed no association with any fat type; survival benefit is driven by cardiovascular and other-cancer mortality reductions.
  • The cohort is predominantly White male health professionals (97% White), which may limit applicability to more diverse patient populations.
  • The 'practice_changing' impact flag reflects a large, well-adjusted cohort with clinically meaningful substitution estimates, but causality cannot be confirmed from an observational study. Clinicians should interpret with appropriate caution.
Show all 4
  • The supplementary tables show some wide confidence intervals for cause-specific mortality endpoints (e.g., other cancer mortality with animal fat: HR 1.49, 95% CI 1.00–2.21), indicating imprecision in secondary outcomes.

Related Questions

Explore related topics

What dietary changes reduce mortality in prostate cancer survivors?Does replacing saturated fat with monounsaturated fat improve outcomes in cancer patients?Plant-based diet and cardiovascular mortality in men with nonmetastatic prostate cancer

Publication Details

Year
2026
Journal
JAMA Network Open
Sample Size
n=4,884
Source
View article
Keep scrolling
More content below.
Up Next